Patents Assigned to KAHR Medical LTD.
-
Publication number: 20240076346Abstract: Type I membrane proteins heterodimers are provided. Accordingly, there is provided a heterodimer comprising two polypeptides selected from the group consisting of SIRPalpha, PD1, TIGIT, LILRB2 and SIGLEC10, wherein each of the two polypeptides is capable of binding a natural binding pair thereof, and wherein the heterodimer does not comprise an amino acid sequence of a type II membrane protein capable of binding a natural binding pair thereof. Also provided are nucleic acid constructs and systems encoding the heterodimer, host-cells expressing same and methods of use thereof.Type: ApplicationFiled: January 13, 2021Publication date: March 7, 2024Applicants: KAHR Medical Ltd., Thomas Jefferson UniversityInventors: Ami TAMIR, Mark L. TYKOCINSKI, Edwin BREMER
-
Patent number: 11897937Abstract: SIRP1alpha-41BBL fusion proteins are provided. Accordingly, there is provided a SIRPalpha-41BBL fusion protein comprising a single amino acid linker between the SIRPalpha and the 41BBL. Also there is provided a SIRPalpha-41BBL fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRP1alpha-41BBL fusion protein, host-cells expressing the SIRP1alpha-41BBL fusion protein and methods of use thereof.Type: GrantFiled: August 12, 2021Date of Patent: February 13, 2024Assignee: KAHR Medical Ltd.Inventors: Noam Shani, Yosi Gozlan, Michal Dranitzki Elhalel, Edwin Bremer, Ido Kaminsky
-
Publication number: 20240010700Abstract: PD1-41BBL fusion proteins are provided. Accordingly, there is provided a PD1-41BBL fusion protein comprising a single amino acid linker between the PD1 and the 41BBL. Also there is provided a PD1-41BBL fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-41BBL fusion protein, host-cells expressing the PD1-41BBL fusion protein and methods of use thereof.Type: ApplicationFiled: June 21, 2023Publication date: January 11, 2024Applicant: KAHR Medical Ltd.Inventors: Mark L. TYKOCINSKI, Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
-
Patent number: 11702458Abstract: PD1-41BBL fusion proteins are provided. Accordingly, there is provided a PD1-41BBL fusion protein comprising a single amino acid linker between the PD1 and the 41BBL. Also there is provided a PD1-41BBL fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-41BBL fusion protein, host-cells expressing the PD1-41BBL fusion protein and methods of use thereof.Type: GrantFiled: January 4, 2018Date of Patent: July 18, 2023Assignee: KAHR Medical Ltd.Inventors: Mark L. Tykocinski, Noam Shani, Yosi Gozlan, Michal Dranitzki Elhalel, Edwin Bremer, Ido Kaminsky
-
Publication number: 20230220040Abstract: PD1-CD70 fusion proteins are provided. Accordingly, there is provided a PD1-CD70 fusion protein comprising a single amino acid linker between the PD1 and the CD70. Also there is provided a PD1-CD70 fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-CD70 fusion protein, host-cells expressing the PD1-CD70 fusion protein and methods of use thereof.Type: ApplicationFiled: January 26, 2023Publication date: July 13, 2023Applicant: KAHR Medical Ltd.Inventors: Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
-
Publication number: 20230048361Abstract: Methods of culturing T cells are provided. Accordingly there is provided a method of culturing T cells comprising adding to immune cells comprising T cells obtained from a subject having a pathology a non-cellular agent capable of binding 4-1BB and activating said 4-1BB signaling pathway; and culturing the immune cells with said agent for more than 7 days. Also provided are T cells obtainable by the method and uses thereof.Type: ApplicationFiled: December 30, 2020Publication date: February 16, 2023Applicants: KAHR Medical Ltd., Beth Israel Deaconess Medical Center, Inc.Inventors: Senthil Kumar MUTHUSWAMY, Manuel HIDALGO MEDINA, Qingda MENG, Yaron PEREG, Ayelet CHAJUT
-
Publication number: 20230048719Abstract: Methods of culturing T cells with a 4-1BBL fusion polypeptide are provided. Accordingly there is provided a method of culturing T cells comprising adding to immune cells comprising T cells obtained from a subject having a pathology a PD1-4-1BBL or a SIRPalpha-4-1BBL fusion polypeptide; and culturing the immune cells with the fusion polypeptide for more than 7 days. Also provided are T cells obtainable by the method and uses thereof.Type: ApplicationFiled: December 30, 2020Publication date: February 16, 2023Applicants: KAHR Medical Ltd., Beth Israel Deaconess Medical Center, Inc.Inventors: Senthil Kumar MUTHUSWAMY, Manuel HIDALGO MEDINA, Qingda MENG, Yaron PEREG, Ayelet CHAJUT
-
Patent number: 11566060Abstract: PD1-CD70 fusion proteins are provided. Accordingly, there is provided a PD1-CD70 fusion protein comprising a single amino acid linker between the PD1 and the CD70. Also there is provided a PD1-CD70 fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-CD70 fusion protein, host-cells expressing the PD1-CD70 fusion protein and methods of use thereof.Type: GrantFiled: January 4, 2018Date of Patent: January 31, 2023Assignee: KAHR Medical Ltd.Inventors: Noam Shani, Yosi Gozlan, Michal Dranitzki Elhalel, Edwin Bremer, Ido Kaminsky
-
Publication number: 20220267409Abstract: Heterodimers are provided. Accordingly, there is provided a heterodimer comprising a dimerizing moiety attached to at least one amino acid sequence of at least one type I membrane protein capable of at least binding a natural ligand or receptor of said at least one type I membrane protein and to at least one amino acid sequence of at least one type II membrane protein capable of at least binding a natural ligand or receptor of said at least one type II membrane protein. Also provided are nucleic acid constructs and systems encoding the heterodimer, host-cells expressing same and methods of use thereof.Type: ApplicationFiled: July 8, 2020Publication date: August 25, 2022Applicants: KAHR Medical Ltd., Thomas Jefferson UniversityInventors: Mark L. TYKOCINSKI, Ami TAMIR, Edwin BREMER
-
Publication number: 20220204586Abstract: SIRPalpha-CD70 fusion proteins are provided. Accordingly, there is provided a SIRPalpha-CD70 fusion protein comprising a single amino acid linker between the SIRPalpha and the CD70. Also there is provided a SIRPalpha-CD70 fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRPalpha-CD70 fusion protein, host-cells expressing the SIRPalpha-CD70 fusion protein and methods of use thereof.Type: ApplicationFiled: March 16, 2022Publication date: June 30, 2022Applicant: KAHR Medical Ltd.Inventors: Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
-
Patent number: 11299530Abstract: SIRPalpha-CD70 fusion proteins are provided. Accordingly, there is provided a SIRPalpha-CD70 fusion protein comprising a single amino acid linker between the SIRPalpha and the CD70. Also there is provided a SIRPalpha-CD70 fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRPalpha-CD70 fusion protein, host-cells expressing the SIRPalpha-CD70 fusion protein and methods of use thereof.Type: GrantFiled: January 4, 2018Date of Patent: April 12, 2022Assignee: KAHR Medical Ltd.Inventors: Noam Shani, Yosi Gozlan, Michal Dranitzki Elhalel, Edwin Bremer, Ido Kaminsky
-
Publication number: 20210371500Abstract: SIRP1alpha-41BBL fusion proteins are provided. Accordingly, there is provided a SIRPalpha-41BBL fusion protein comprising a single amino acid linker between the SIRPalpha and the 41BBL. Also there is provided a SIRPalpha-41BBL fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRP1alpha-41BBL fusion protein, host-cells expressing the SIRP1alpha-41BBL fusion protein and methods of use thereof.Type: ApplicationFiled: August 12, 2021Publication date: December 2, 2021Applicant: KAHR Medical Ltd.Inventors: Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
-
Patent number: 11130796Abstract: SIRP1alpha-41BBL fusion proteins are provided. Accordingly, there is provided a SIRPalpha-41BBL fusion protein comprising a single amino acid linker between the SIRPalpha and the 41BBL. Also there is provided a SIRPalpha-41BBL fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRP1alpha-41BBL fusion protein, host-cells expressing the SIRP1alpha-41BBL fusion protein and methods of use thereof.Type: GrantFiled: January 4, 2018Date of Patent: September 28, 2021Assignee: KAHR Medical Ltd.Inventors: Noam Shani, Yosi Gozlan, Michal Dranitzki Elhalel, Edwin Bremer, Ido Kaminsky
-
Publication number: 20210284711Abstract: PD1-4-1BBL variant fusion proteins are provided. Also provided are isolated polypeptides comprising a PD1 variant or a 4-1BBL variant. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-4-1BBL fusion protein or the isolated polypeptide, host-cells expressing the same and methods of use thereof.Type: ApplicationFiled: July 11, 2019Publication date: September 16, 2021Applicant: KAHR Medical Ltd.Inventors: Iris PECKER, Itai BLOCH
-
Publication number: 20210214417Abstract: SIRPalpha-4-1BBL variant fusion proteins are provided. Also provided are isolated polypeptides comprising a SIRPalpha variant. Also provided are polynucleotides and nucleic acid constructs encoding the SIRPalpha-41BBL fusion protein or the isolated polypeptide, host-cells expressing same and methods of use thereof.Type: ApplicationFiled: July 11, 2019Publication date: July 15, 2021Applicant: KAHR Medical Ltd.Inventors: Iris PECKER, Itai BLOCH
-
Publication number: 20190352371Abstract: PD1-41BBL fusion proteins are provided. Accordingly, there is provided a PD1-41BBL fusion protein comprising a single amino acid linker between the PD1 and the 41BBL. Also there is provided a PD1-41BBL fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-41BBL fusion protein, host-cells expressing the PD1-41BBL fusion protein and methods of use thereof.Type: ApplicationFiled: January 4, 2018Publication date: November 21, 2019Applicant: KAHR Medical Ltd.Inventors: Mark L. TYKOCINSKI, Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
-
Publication number: 20190352372Abstract: SIRP1alpha-41BBL fusion proteins are provided. Accordingly, there is provided a SIRPalpha-41BBL fusion protein comprising a single amino acid linker between the SIRPalpha and the 41BBL. Also there is provided a SIRPalpha-41BBL fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRP1alpha-41BBL fusion protein, host-cells expressing the SIRP1alpha-41BBL fusion protein and methods of use thereof.Type: ApplicationFiled: January 4, 2018Publication date: November 21, 2019Applicant: KAHR Medical Ltd.Inventors: Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
-
Publication number: 20190330304Abstract: PD1-CD70 fusion proteins are provided. Accordingly, there is provided a PD1-CD70 fusion protein comprising a single amino acid linker between the PD1 and the CD70. Also there is provided a PD1-CD70 fusion protein, wherein the PD1 amino acid is 123-166 amino acids in length and/or wherein the PD1 amino acid sequence comprises SEQ ID NO: 2 and/or wherein the fusion protein is in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the PD1-CD70 fusion protein, host-cells expressing the PD1-CD70 fusion protein and methods of use thereof.Type: ApplicationFiled: January 4, 2018Publication date: October 31, 2019Applicant: KAHR Medical Ltd.Inventors: Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
-
STABLE FORM OF SIGNAL CONVERTING PROTEIN FUSION PROTEINS, AND METHODS OF USE AND PREPARATION THEREOF
Publication number: 20190016782Abstract: A stable fusion protein, wherein in solution, a majority of the fusion proteins are in the homo-hexamer form, which may be prepared for example as a CTLA4-FasL fusion protein.Type: ApplicationFiled: July 5, 2018Publication date: January 17, 2019Applicant: KAHR Medical Ltd.Inventors: Michal DRANITZKI ELHALEL, Noam SHANI -
Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
Patent number: 10040841Abstract: A stable fusion protein, wherein in solution, a majority of the fusion proteins are in the homo-hexamer form, which may be prepared for example as a CTLA4-FasL fusion protein.Type: GrantFiled: December 31, 2013Date of Patent: August 7, 2018Assignee: KAHR Medical Ltd.Inventors: Michal Dranitzki Elhalel, Noam Shani